Clearmind Medicine Inc.
NNASDAQ:CMNDCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Adi Zuloff-Shani
- Full Time Employees
- 4
- Sector
- Non-energy minerals
- Industry
- Other metals/Minerals
- Address
- 1220 West 6th Avenue Vancouver BC Canada V6H 1A5
- IPO Date
- Nov 15, 2022
- CIK
- 0001892500
- Website
- clearmindmedicine.com
- Similar Companies
- Business
- Clearmind Medicine Inc. is a clinical-stage pharmaceutical company that develops novel psychedelic-derived medicines aimed at treating widespread and under-served health problems. The company’s core product offerings include psychedelic-based therapeutics targeting alcohol use disorders, binge drinking, eating disorders, weight loss, obesity, metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment-resistant depression. Its key products under development are the MEAI compound for treating alcohol use disorder, obesity, and metabolic disorders, including an alcohol substitute consumer product, and CM-CMND-001, currently in Phase I/IIa clinical trials for alcohol use disorder treatment. The company also explores combination treatments for obesity and metabolic syndrome through collaborations. Recent major changes include a strategic partnership with Dr. Glitter Pty Ltd to co-develop and commercialize an MEAI-based alcohol substitute using Dr. Glitter’s ActivCrystal™ technology, an innovative oral delivery format that enables flexible consumption by sprinkling the product onto food or beverages. This partnership aims to provide a safer alternative to traditional alcohol consumption, addressing alcohol misuse and related health risks. Additionally, Clearmind obtained final regulatory approval from Hadassah Medical Center in Jerusalem to expand its Phase 1/2a clinical trial for CMND-100, furthering its multinational studies that include leading medical centers such as Yale and Johns Hopkins. The company has also engaged JS First Sdn. Bhd to source global manufacturers and distributors, supporting its international expansion plans. Furthermore, Clearmind secured $10 million in a securities purchase agreement to advance strategic opportunities and has recently filed for patents related to novel non-hallucinogenic neuroplastogen treatments for depression. Operating primarily in the biotechnology and healthcare sectors, Clearmind Medicine targets mental health and metabolic disease markets worldwide. Founded in 2017, the company is headquartered in Vancouver, Canada. It maintains a collaborative research relationship with Yissum Research Development Company of the Hebrew University of Jerusalem for developing and commercializing compounds for PTSD and other conditions. The company was formerly known as Cyntar Ventures Inc. until its name change to Clearmind Medicine Inc. in March 2021. Clearmind’s broad clinical pipeline and strategic alliances position it as an innovator in psychedelic medicine development with a focus on transforming treatment options for alcohol-related and mental health disorders.
Company News
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Clearmind Medicine Stock Slides Friday: What's Happening?
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial